Investigating alpha-synuclein co-pathology in Alzheimer's disease by means of cerebrospinal fluid alpha-synuclein seed amplification assay.

Giovanni Bellomo Andrea Toja Federico Paolini PaolettiYihua MaCarly M Farris Lorenzo GaetaniNicola SalvadoriDavide Chiasserini Anna Lidia Wojdaƚa Luis Concha-Marambio Lucilla Parnetti

Published in: Alzheimer's & dementia : the journal of the Alzheimer's Association (2024)

αS-SAA positivity in AD patients reflects the prevalence observed in neuropathological series and is associated with a worse clinical outcome. These data confirm the validity of CSF αS-SAA positivity as biomarker of synucleinopathy.

Keyphrases

cerebrospinal fluid
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
risk factors
peritoneal dialysis
cognitive decline
big data
high throughput
deep learning
data analysis